TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27225678
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (precontoured locking plates placed either superiorly or anteriorly)
Study: 21857363
Drug: Tapering after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering after training (2 weeks)
Study: 21857363
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of MTG and ETG after training and tapering
Study: 2390429
Drug: Atropine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (both doses)
Study: 7308274
Drug: F‐CBZ, DAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: F‐CBZ, DAK (200 mg single dose)
Study: 7308274
Drug: Tegretol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol (200 mg single dose)
Study: 29241199
Drug: Darbepoetin therapy
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin therapy
Study: 25401463
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) therapy (40 sessions at 1.5 ATA)
Study: 23752553
Drug: Positive expiratory
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive expiratory pressure (PEP) therapy (10‐20 cm H2O)
Study: 17318022
Drug: LCT genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT genotype CC (associated with lactose malabsorption)
Study: 15203784
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (fast delivery)
Study: 15203784
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (slow delivery)
Study: 15203784
Drug: Placebo condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo condition (placebo spray and patch)
Study: 15203784
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch condition (with placebo spray)
Study: 15203784
Drug: Nicotine spray
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine spray condition (with placebo patch)
Study: 11181775
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine without adjuvant (10-50 microg doses)
Study: 11181775
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine with MF59 adjuvant (10-50 microg doses)
Study: 11181775
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine with alum adjuvant (10-50 microg doses)
Study: 2114722
Drug: Adjuvant portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant portal infusion of 5‐fluorouracil in combination with mitomycin C
Study: 2114722
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (strict adherence)
Study: 2114722
Drug: No or
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No or incomplete chemotherapy
Study: 19912735
Drug: Gengnianan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gengnianan Tablet (control)
Study: 14674971
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg(‐1) followed by remifentanil 1 microg kg(‐1) (group PR)
Study: 14674971
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg kg(‐1) followed by propofol 2.5 mg kg(‐1) (group RP)
Study: 11739068
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with nortriptyline-plus-perphenazine
Study: 11739068
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with nortriptyline-plus-placebo
Study: 9770818
Drug: Propofol without
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol without narcotic analgesics
Study: 9770818
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with pyritramide (0.4 mg/kg)
Study: 9770818
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of propofol
Study: 9770818
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of thiopental
Study: 9357148
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose choline (500 mg TDS)
Study: 9357148
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose choline (1000 mg TDS)
Study: 29310326
Drug: remifentanil (infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (infused at 2 μg/kg/h)
Study: 29310326
Drug: dexmedetomidine (infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine (infused at 0.4 μg/kg/h)
Study: 16180017
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of change agents as part of the intervention.
Study: 11413351
Drug: Formoterol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (24 microg twice daily by Turbuhaler)
Study: 11413351
Drug: Salmeterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (100 microg twice daily by Diskhaler)
Study: 28455162
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (sphincterotomy)
Study: 26178282
Drug: Intraarticular etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraarticular etanercept injection
Study: 22952137
Drug: No solution
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No solution (CON)
Study: 21733322
Drug: PF-rich extract
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-rich extract (500 mg daily)
Study: 19502035
Drug: Pre-warmed colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-warmed colloid followed by pre-warmed crystalloid solution
Study: 19502035
Drug: Non-warmed infusion
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-warmed infusion
Study: 16430793
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (droperidol 2.5 mg)
Study: 16430793
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (droperidol 2.5 mg 2 day(‐1))
Study: 10883558
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) with breathing retraining (BR)
Study: 10883558
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) without breathing retraining (BR)
Study: 9166393
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (400 mg/day for 2 weeks, followed by 11 weeks of 500 mg/day elemental oral calcium)
Study: 9166393
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist alone (triptorelin 3.75 mg intramuscularly every 4 weeks)
Study: 9166393
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium (500 mg/day continuously)
Study: 8222488
Drug: Drug-free vehicles
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free vehicles
Study: 2988108
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (Guarem), 5 g
Study: 2988108
Drug: Fiber-enriched wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-enriched wheat bran (Fiberform), 10.5 g
Study: 24832191
Drug: BAl (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAl (4.8 g day(‐1) for 4 weeks, increased to 6.4 g day(‐1) for 2 weeks)
Study: 22877888
Drug: CBT-based stress-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-based stress-management treatment (SM)
Study: 6886969
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg caffeine as aqueous oral solution
Study: 6886969
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg caffeine as intravenous infusion over 30 min
Study: 30658460
Drug: Wheat albumin
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat albumin (WA) 1.5 g
Study: 26345338
Drug: Naltrexone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone therapy (4 weeks, oral administration)
Study: 26345338
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 weeks, oral administration)
Study: 23974801
Drug: ART +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART + Carisolv® gel
Study: 22695473
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/d) plus Twelve Step Facilitation (TSF)
Study: 22695473
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/d) plus standard counseling
Study: 17580147
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg by intravenous infusion 2 hours before operation)
Study: 11886767
Drug: Vitamin K(2)
Normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K(2) and D(3) combined therapy for 24 months
Study: 11886767
Drug: Vitamin K(2)
Normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K(2) therapy alone for 24 months
Study: 11886767
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving dietary therapy alone
Study: 10334534
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT), n = 39
Study: 10334534
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormones), n = 280
Study: 8547939
Drug: 8% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% glucose solution (CHO)
Study: 8547939
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (PL)
Study: 30841568
Drug: Non-steroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid anti-inflammatory drugs (NSAIDs) use
Study: 27322597
Drug: Guarana 50
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guarana 50 mg twice a day during chemoradiotherapy
Study: 21716983
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine digluconate solution used twice daily for 3 months
Study: 19699918
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion at 4 cc/hour for 100 hours
Study: 19699918
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline solution) infusion
Study: 12724679
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion
Study: 3898670
Drug: Dipyridamole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (8 mg for adults, 50 mg for schoolchildren, 24 mg for kindergarten children) administered orally every 8 days during the epidemic period (January-March 1983)
Study: 29743334
Drug: High water
Normalized name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High water (HW) intake based on an individualised water intake prescription
Study: 26467700
Drug: Relamorelin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin, 100 μg, SQ
Study: 25812762
Drug: Best endovascular
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best endovascular therapy
Study: 25812762
Drug: Best open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best open surgical treatment
Study: 21474566
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (upper canines)
Study: 21474566
Drug: Miniscrew group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miniscrew group (miniscrew implants)
Study: 11083486
Drug: Rutin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin supplementation (500 mg)
Study: 8633816
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (zidovudine with didanosine or zalcitabine)
Study: 8633816
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy (with didanosine or zalcitabine)
Study: 1997702
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment (150 micrograms ethinyl estradiol daily and 80 mg polyestradiol monthly)
Study: 31809265
Drug: Additional oral
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional oral medications (0, 1, or 2+ medications)
Study: 31809265
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) in girls
Study: 15656907
Drug: Conservative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative care protocol (visits with a hand therapist, exercises, self-care booklet, work modification/activity restriction, B6 therapy, ultrasound, possible steroid injections)
Study: 1782100
Drug: Control day
Normalized name: Avobenzone 30 mg in 1 mL / Octinoxate 75 mg in 1 mL TOPICAL LOTION [Oil-Control Day SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control day (no treatment)
Study: 30626939
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of Notch signaling using neutralizing antibody or pharmaceutical inhibitor
Study: 28353593
Drug: Warming infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming infusion (fluid warmed to 35°C)
Study: 28353593
Drug: Control (room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (room temperature infusion at 22-23°C)
Study: 26514332
Drug: Buccal spray
Normalized name: Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal spray (500 IU, delivering 1000 IU in two spray shots)
Study: 26514332
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule (1000 IU)
Study: 11344204
Drug: Morning hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning hypoglycemia (2.9 +/‐ 0.1 mmol/L)
Study: 11344204
Drug: Euglycemic control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic control (5.1 +/‐ 0.1 mmol/L)
Study: 10437184
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no change in prescribed medication)
Study: 2580866
Drug: Acebutolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (600 mg tid)
Study: 2580866
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg tid)
Study: 31020598
Drug: Dosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of low-molecular-weight heparins (LMWHs)
Study: 24891327
Drug: LVR coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVR coil treatment
Study: 20650046
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 0.2 microg/kg/min (G1)
Study: 20650046
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 0.2 microg/kg/min and low doses of ketamine infusion 1 microg/kg/min (G2)
Study: 8772222
Drug: Synthetic natural
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic natural pentasaccharide (NP) administered subcutaneously at doses from 1.43 to 22.9 mg (1000 to 16,000 anti‐Xa IU)
Study: 8772222
Drug: Synthetic natural
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic natural pentasaccharide (NP) administered at various dosages once or twice a day for 7 days
Study: 8772222
Drug: Synthetic natural
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic natural pentasaccharide (NP) at highest dose regimens (single injection of 26.6 mg and repeated injections of 11.4 mg)
Study: 2292115
Drug: TCM prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM prescriptions of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy
Study: 2292115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chinese medicine with chemotherapy
Study: 26401735
Drug: Intravenous sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sugammadex (2 mg kg⁻¹)
Study: 26401735
Drug: No reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reversal agents (Control Group II)
Study: 24098467
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg/day) in DM subgroup (n = 63)
Study: 24098467
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day) in DM subgroup (n = 62)
Study: 21320950
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy (melphalan with or without topotecan)
Study: 19158122
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral theophylline (100 mg twice daily)
Study: 19158122
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (including systemic steroids)
Study: 8061738
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody treatment for endotoxin-induced septic shock
Study: 8061738
Drug: New techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: New techniques to supplement basic cardiopulmonary resuscitation
Study: 8061738
Drug: Ribavirin treatment
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin treatment for respiratory syncytial virus infection in mechanically ventilated infants
Study: 2969169
Drug: 2 l
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l O2/min
Study: 2969169
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l O2/min
Study: 31729999
Drug: Immediate antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiretroviral therapy (ART) starting within 7 days after initiation of opportunistic infection (OI) treatment
Study: 31729999
Drug: Deferred antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiretroviral therapy (ART) starting after completing OI-therapy
Study: 22204723
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg daily) plus elastic stockings with graduated compression
Study: 18196200
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment during TMS
Study: 10711861
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (9 g daily for 1 month)
Study: 26300945
Drug: Sanfu herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanfu herbal patch (SHP)
Study: 21226939
Drug: Titrated therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated therapeutic hypothermia (32-35 °C) with intravenous 0.9% saline (20-30 ml/kg) and maintained for at least 48 hours or longer as needed to keep intracranial pressure <20 mmHg.
Study: 18653816
Drug: Medication Discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Discharge Plan (MDP)
Study: 11410720
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day)
Study: 9248764
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) 60 mg.kg-1 on day 1 plus calcitriol 1 microgram per day orally for 5 consecutive days
Study: 9248764
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) 60 mg.kg-1 on day 1
Study: 8363113
Drug: N‐acetylcysteine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetylcysteine (140 mg/kg)
Study: 8363113
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (60 g) + N‐acetylcysteine (235 mg/kg)
Study: 3306781
Drug: Iopamidol (nonionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (nonionic agent)